Shopping Cart 0
Cart Subtotal
USD 0

Insmed Inc (INSM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Insmed Inc (Insmed) is a biopharmaceutical company that focuses on rare diseases. Its lead product candidate, Arikayce (liposomal amikacin for inhalation), is indicated for the treatment of nontuberculous mycobacteria (NTM) lung disease in adult patients. Its other clinical pipeline are being developed for pulmonary arterial hypertension (PAH), severe refractory asthma, for chronic inflammatory lung diseases such as non-cystic fibrosis (non-CF) bronchiectasis and for nontuberculous mycobacterial lung infection and chronic Pseudomonas aeruginosa in non-CF bronchiectasis. The company has offices in the US, the UK, Ireland, the Netherlands, Germany and France. Insmed is headquartered in Bridgewater, New Jersey, the US.

Insmed Inc (INSM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Insmed Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Insmed Inc, Medical Devices Deals, 2012 to YTD 2018 9

Insmed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Insmed Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Insmed Enters into Agreement with National Institutes of Allergy and Infectious Diseases 11

Licensing Agreements 12

Insmed Enters into Licensing Agreement with AstraZeneca 12

Premacure Amends Licensing Agreement with Insmed 14

Equity Offering 15

Insmed Raises USD402 Million in Public Offering of Shares 15

Insmed Raises USD237.4 Million in Public Offering of Common Stock 17

Insmed Raises USD115 Million in Public Offering of Shares 19

Insmed Completes Public Offering Of Shares For USD 71.8 Million 21

Insmed Completes Public Offering Of Common Stock For USD 26 Million 23

Debt Offering 24

Insmed Raises USD450 Million in Public Offering of 1.75% Notes Due 2025 24

Insmed Inc-Key Competitors 26

Insmed Inc-Key Employees 27

Insmed Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Oct 30, 2018: Insmed reports third quarter 2018 financial results and provides business update 29

Aug 02, 2018: Insmed reports second quarter 2018 financial Results and provides business update 31

May 02, 2018: Insmed Reports First Quarter 2018 Financial Results and Provides Business Update 33

Feb 23, 2018: Insmed Reports Fourth Quarter 2017 Financial Results 34

Nov 02, 2017: Insmed Reports Third Quarter 2017 Financial Results and Provides Business Update 36

Aug 03, 2017: Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update 37

May 03, 2017: Insmed Reports First Quarter 2017 Financial Results 38

May 03, 2017: Insmed Q1 net loss increases 39

Feb 23, 2017: Insmed Reports Fourth Quarter 2016 Financial Results and Provides Business Update 40

Corporate Communications 41

May 15, 2017: Insmed Announces Key Additions to its Executive Management Team 41

Clinical Trials 42

May 03, 2017: Insmed Provides Update On Phase 2 Study Of INS1007 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List Of Figure

List of Figures

Insmed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Insmed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Insmed Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Insmed Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Insmed Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Insmed Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Insmed Inc, Medical Devices Deals, 2012 to YTD 2018 9

Insmed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Insmed Enters into Agreement with National Institutes of Allergy and Infectious Diseases 11

Insmed Enters into Licensing Agreement with AstraZeneca 12

Premacure Amends Licensing Agreement with Insmed 14

Insmed Raises USD402 Million in Public Offering of Shares 15

Insmed Raises USD237.4 Million in Public Offering of Common Stock 17

Insmed Raises USD115 Million in Public Offering of Shares 19

Insmed Completes Public Offering Of Shares For USD 71.8 Million 21

Insmed Completes Public Offering Of Common Stock For USD 26 Million 23

Insmed Raises USD450 Million in Public Offering of 1.75% Notes Due 2025 24

Insmed Inc, Key Competitors 26

Insmed Inc, Key Employees 27

Insmed Inc, Subsidiaries 28

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Insmed Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Insmed Inc (Insmed) is a biopharmaceutical company that focuses on rare diseases. Its lead product candidate, Arikayce (liposomal amikacin for inhalation), is indicated for the treatment of nontuberculous mycobacteria (NTM) lung disease in adult patients. Its other clinical pipeline are being developed for pulmonary arterial hypertension (PAH), severe refractory asthma, for chronic inflammatory lung diseases such as non-cystic fibrosis (non-CF) bronchiectasis and for nontuberculous mycobacterial lung infection and chronic Pseudomonas aeruginosa in non-CF bronchiectasis. The company has offices in the US, the UK, Ireland, the Netherlands, Germany and France. Insmed is headquartered in Bridgewater, New Jersey, the US.

Insmed Inc (INSM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Insmed Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Insmed Inc, Medical Devices Deals, 2012 to YTD 2018 9

Insmed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Insmed Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Insmed Enters into Agreement with National Institutes of Allergy and Infectious Diseases 11

Licensing Agreements 12

Insmed Enters into Licensing Agreement with AstraZeneca 12

Premacure Amends Licensing Agreement with Insmed 14

Equity Offering 15

Insmed Raises USD402 Million in Public Offering of Shares 15

Insmed Raises USD237.4 Million in Public Offering of Common Stock 17

Insmed Raises USD115 Million in Public Offering of Shares 19

Insmed Completes Public Offering Of Shares For USD 71.8 Million 21

Insmed Completes Public Offering Of Common Stock For USD 26 Million 23

Debt Offering 24

Insmed Raises USD450 Million in Public Offering of 1.75% Notes Due 2025 24

Insmed Inc-Key Competitors 26

Insmed Inc-Key Employees 27

Insmed Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Oct 30, 2018: Insmed reports third quarter 2018 financial results and provides business update 29

Aug 02, 2018: Insmed reports second quarter 2018 financial Results and provides business update 31

May 02, 2018: Insmed Reports First Quarter 2018 Financial Results and Provides Business Update 33

Feb 23, 2018: Insmed Reports Fourth Quarter 2017 Financial Results 34

Nov 02, 2017: Insmed Reports Third Quarter 2017 Financial Results and Provides Business Update 36

Aug 03, 2017: Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update 37

May 03, 2017: Insmed Reports First Quarter 2017 Financial Results 38

May 03, 2017: Insmed Q1 net loss increases 39

Feb 23, 2017: Insmed Reports Fourth Quarter 2016 Financial Results and Provides Business Update 40

Corporate Communications 41

May 15, 2017: Insmed Announces Key Additions to its Executive Management Team 41

Clinical Trials 42

May 03, 2017: Insmed Provides Update On Phase 2 Study Of INS1007 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List Of Figure

List of Figures

Insmed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Insmed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Insmed Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Insmed Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Insmed Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Insmed Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Insmed Inc, Medical Devices Deals, 2012 to YTD 2018 9

Insmed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Insmed Enters into Agreement with National Institutes of Allergy and Infectious Diseases 11

Insmed Enters into Licensing Agreement with AstraZeneca 12

Premacure Amends Licensing Agreement with Insmed 14

Insmed Raises USD402 Million in Public Offering of Shares 15

Insmed Raises USD237.4 Million in Public Offering of Common Stock 17

Insmed Raises USD115 Million in Public Offering of Shares 19

Insmed Completes Public Offering Of Shares For USD 71.8 Million 21

Insmed Completes Public Offering Of Common Stock For USD 26 Million 23

Insmed Raises USD450 Million in Public Offering of 1.75% Notes Due 2025 24

Insmed Inc, Key Competitors 26

Insmed Inc, Key Employees 27

Insmed Inc, Subsidiaries 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Insmed Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.